Ad Hoc Announcements
Important information for immediate release
Formycon also provides ad hoc announcements in compliance with Section 17 of the Regulation (EU) No 596/2014 of the European Parliament and of the Council (Market Abuse Regulation), which requires public companies to publish any company news that could significantly influence share price.
Formycon informs about the modified BLA-Submission Strategy for its Lucentis(R)* Biosimilar-Candidate FYB201
Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) and its licensing partner Bioeq AG ("Bioeq") announced today that the Biologics License Application (BLA) resubmission strategy for FYB201 has been adjusted.
The approval for FYB201 will be requested directly for a large commercial...
November 5, 2020
Formycon places Cash Capital Increase of 25.75 Million Euros with Strategic Investor
Munich - The Management Board of Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) resolved yesterday, with the approval of the Supervisory Board, to increase the company's capital against cash contributions by partially utilizing the approved capital. The Company's share capital of currently EUR...
October 12, 2020
Formycon informs about the current Status of the BLA Review Process of the Lucentis®Biosimilar Candidate FYB201
Formycon AG and its licensing partner Bioeq announce today, that the U.S. Food and Drug Administration (FDA) has requested additional data as part of the review process of the BLA for the Lucentis® biosimilar candidate FYB201, submitted by Bioeq in December 2019.
February 4, 2020
Bioeq IP AG Exclusively Licenses US Marketing Rights For FYB201 To Coherus BioSciences, Inc.
Bioeq IP AG, the exclusive owner of the global commercialization rights of Formycon’s FYB201 has signed a license and development agreement with Coherus BioSciences, Inc. The US Biosimilar-specialist, headquartered in California, will exclusively market and distribute Formycon's biosimilar candidate to Lucentis® (FYB201) in the United States of America (US).
November 6, 2019
Formycon Reports Further Course of Capital Measure
With the agreement dated June 26, 2019, Wendeln & Cie. KG, an asset management company of Mr. Peter Wendeln (anchor shareholder and long-standing member of the Supervisory Board of Formycon AG), acquired all rights from the certificate of subscription as well as the 577,397 shares in Formycon AG from the cash capital increase.
June 26, 2019
Formycon Reports Latest Status of Capital Increase
As of today, totaling EUR 5,000,000.00, have been paid to the company’s capital increase account. The signatory's debt contribution amounting to EUR 12,264,170.30 is therefore still outstanding. The shares have so far not been delivered due to the as yet unsettled payment.
June 3, 2019
Formycon Places Cash Capital Increase of EUR 17.3 Million with Institutional Investor
Strategic investor M&H Equity AG subscribes for a cash capital increase of € 17,264,170.30 million in the context of a private placement with an issue price of 29.90 EUR per share. The funds acquired from the capital increase will be used primarily to develop the company’s own biosimilar products, particularly FYB205.
March 22, 2019
Biosimilar Candidate FYB201 Shows Efficacy Comparable to the Reference Product in Phase III Study
According to an interim result, the primary endpoint has been achieved in the COLUMBUS-AMD phase III trial, which is intended to demonstrate the efficacy, safety and immunogenicity of FYB201 and the reference medicinal product Lucentis® in patients with neovascular age-related macular degeneration (nAMD).
May 2, 2018
Formycon and Aristo Pharma are Founding a Joint Venture for the Development of FYB202
Formycon and Aristo Pharma GmbH, a company of the Struengmann-Group, have formed a joint company for the continued development of FYB202, Formycon's biosimilar candidate for Stelara® (ustekinumab).
December 22, 2017
Formycon signs term sheet for development of FYB202 and executes capital increase
Formycon plans to enter into a co-investment arrangement for its biosimilar candidate FYB202 and aims for a participation of up to 30% in worldwide marketing proceeds.
July 24, 2017